ANECTINE Drug Patent Profile

« Back to Dashboard

Which patents cover Anectine, and what generic alternatives are available?

Anectine is a drug marketed by Sandoz and is included in one NDA.

The generic ingredient in ANECTINE is succinylcholine chloride. There is one drug master file entry for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the succinylcholine chloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Anectine

A generic version of ANECTINE was approved as succinylcholine chloride by ZYDUS PHARMS on May 4^th, 2018.

Summary for ANECTINE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	43
Clinical Trials:	1
Patent Applications:	1,526
Drug Prices:	Drug price information for ANECTINE
What excipients (inactive ingredients) are in ANECTINE?	ANECTINE excipients list
DailyMed Link:	ANECTINE at DailyMed

See drug prices for ANECTINE

Recent Clinical Trials for ANECTINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Hospital, Geneva	Phase 2
University of Lausanne Hospitals	Phase 2

See all ANECTINE clinical trials

Pharmacology for ANECTINE

Drug Class	Depolarizing Neuromuscular Blocker
Physiological Effect	Neuromuscular Depolarizing Blockade

US Patents and Regulatory Information for ANECTINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	ANECTINE	succinylcholine chloride	INJECTABLE;INJECTION	008453-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Sandoz	ANECTINE	succinylcholine chloride	INJECTABLE;INJECTION	008453-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Sandoz	ANECTINE	succinylcholine chloride	INJECTABLE;INJECTION	008453-002	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes
Sandoz	ANECTINE	succinylcholine chloride	INJECTABLE;INJECTION	008453-003	Approved Prior to Jan 1, 1982		DISCN	No	No

Anectine Market Dynamics and Financial Trajectory: Succinylcholine Injection Analysis

Last updated: October 29, 2026

Anectine is a legacy brand of succinylcholine chloride injection, a short-acting depolarizing neuromuscular blocker used primarily for rapid tracheal intubation, electroconvulsive therapy, and selected emergency procedures. Its commercial profile is defined by low unit pricing, generic competition, hospital-contract purchasing, limited differentiation, and recurring supply-risk episodes. Standalone Anectine revenue, market share, and profitability are not publicly reported. The economic value sits primarily in reliable manufacturing, regulatory continuity, and hospital supply access rather than brand pricing power.

What is Anectine and how is it used?

Anectine contains succinylcholine chloride, also known as suxamethonium in several non-U.S. markets. It produces rapid skeletal-muscle paralysis through persistent depolarization at the neuromuscular junction. The effect begins quickly and usually resolves within minutes because the drug is rapidly hydrolyzed by plasma cholinesterase.[1]

Attribute	Anectine
Active ingredient	Succinylcholine chloride
Drug class	Depolarizing neuromuscular blocker
Primary use	Rapid-sequence and emergency intubation
Other uses	Short procedures and electroconvulsive therapy
Typical administration	Intravenous or intramuscular injection
Prescription status	Hospital and prescription medicine
Commercial category	Mature generic injectable
Principal substitutes	Rocuronium, vecuronium, atracurium and other neuromuscular blockers
Key safety constraints	Hyperkalemia, malignant hyperthermia, bradycardia and prolonged paralysis

Anectine is not a chronic-use medicine. Demand is linked to procedure volume, emergency medicine, anesthesia practice, intensive-care activity, and hospital stocking protocols. The product is also used as a stocked emergency drug, which creates demand that is less sensitive to daily procedure utilization than many elective medicines.

What is the FDA regulatory status of Anectine?

Anectine is regulated as an injectable prescription drug. Its U.S. commercial position is based on an old active pharmaceutical ingredient and established clinical use rather than a recent innovation or exclusivity grant.

The principal regulatory issues are:

• sterile injectable manufacturing compliance;
• product availability and shortage management;
• concentration and presentation differences;
• preservative status;
• labeling for high-risk adverse events;
• hospital pharmacy substitution and purchasing contracts.

The U.S. label warns against use in patients with susceptibility to malignant hyperthermia and in several conditions associated with severe hyperkalemia. The label also addresses bradycardia, cardiac arrest, prolonged apnea, and atypical plasma cholinesterase activity.[1]

FDA approval of succinylcholine products does not create meaningful modern market exclusivity for Anectine. The molecule has been used clinically for decades, and competing abbreviated new drug applications and legacy injectable products can enter where regulatory requirements are met.

What is the Orange Book status of Anectine?

Anectine does not have a commercially meaningful patent-based exclusivity position in the U.S. market. The active ingredient is a longstanding generic compound, and the relevant commercial protection does not come from composition-of-matter patent rights.

Exclusivity category	Anectine position
New chemical entity exclusivity	Expired or not commercially relevant
Pediatric exclusivity	No current commercially material protection identified
Orphan exclusivity	Not applicable
New formulation exclusivity	No material current protection identified
Orange Book patent blocking	No material patent barrier identified
Generic substitution risk	High
Product differentiation	Low

Orange Book exposure should be assessed at the specific approved product and NDA level because brand history and current marketing status can differ across jurisdictions. The business conclusion remains unchanged: Anectine is an off-patent injectable product competing primarily on supply, price, quality, and formulary access.

When does Anectine lose exclusivity?

Anectine has already passed the commercially relevant loss-of-exclusivity period. There is no anticipated patent cliff comparable to a branded small-molecule medicine with an upcoming composition patent expiration.

The practical exclusivity timeline is:

Period	Commercial position
Original launch era	Branded hospital anesthetic and neuromuscular-blocker product
Generic-entry period	Succinylcholine injection became available from multiple manufacturers
Current market	Mature, low-price injectable market with supply-driven economics
Forward outlook	No expected patent-driven revenue event

Any future erosion is likely to result from additional generic suppliers, contract-price reductions, formulation substitution, or reduced use of succinylcholine in favor of rocuronium and other nondepolarizing agents.

How many patents cover Anectine?

No material, enforceable patent estate is associated with the core succinylcholine chloride molecule. The compound is an established active ingredient, and its principal commercial presentations are conventional sterile injections.

Potential patent categories in this market would include:

• container-closure systems;
• ready-to-use presentations;
• prefilled syringes;
• stability improvements;
• manufacturing processes;
• packaging and storage systems.

These categories do not appear to provide Anectine with a significant current market barrier. Any patent analysis must separate historical patents from live, enforceable rights and distinguish the branded product from competing succinylcholine products.

What drives the Anectine market?

Hospital and emergency procedure demand

Demand is concentrated in hospitals, ambulatory surgical centers, emergency departments, intensive-care units, and electroconvulsive-therapy facilities. Emergency airway management supports baseline demand because succinylcholine remains familiar to clinicians and has a rapid onset and short duration.

Competitive substitution

Rocuronium is the most important clinical substitute in many intubation protocols. It has a longer duration of action but is widely used for rapid-sequence induction and can be reversed with sugammadex in appropriate circumstances. Vecuronium and other nondepolarizing neuromuscular blockers compete in operating-room and intensive-care settings.

Clinical substitution reduces Anectine's pricing power. Hospitals can shift protocols when supply is constrained, safety preferences change, or the relative cost of succinylcholine, rocuronium, and reversal agents changes.

Supply reliability

Sterile injectable markets are vulnerable to production interruptions because they require validated aseptic processing, specialized facilities, quality-control testing, and regulatory inspection readiness. A small number of qualified manufacturers can create disproportionate shortage risk even when the underlying molecule is old and inexpensive.

FDA's drug-shortage database has repeatedly treated injectable neuromuscular blockers and other hospital injectables as supply-sensitive products. Shortage conditions can temporarily raise the value of available inventory, but they do not create durable brand pricing power.[2]

Purchasing concentration

Purchasing is usually managed through group purchasing organizations, hospital systems, wholesalers, and institutional contracts. The largest purchasing organizations can pressure suppliers on price. Winning share therefore depends on:

• reliable fill rates;
• approved supplier status;
• national distribution;
• product concentration and vial configuration;
• shortage performance;
• quality history;
• contract pricing.

What is the financial trajectory of Anectine?

Standalone revenue for Anectine is not publicly disclosed. The product is generally reported within broader portfolios of hospital injectables, anesthesia products, or generic medicines. Public-company filings do not typically provide product-level sales, gross margin, or operating-profit data for this brand.

The financial trajectory can be characterized as follows:

Financial driver	Expected effect
Mature generic status	Sustained price pressure
Low-cost active ingredient	Limits unit economics
Sterile injectable production	Raises manufacturing and compliance costs
Hospital contracts	Compresses gross margin
Shortage events	Can increase near-term volume and price
Multiple suppliers	Limits durable price expansion
Emergency-stock requirement	Supports recurring baseline demand
Substitution by rocuronium	Limits long-term volume growth
Brand recognition	Provides limited pricing benefit

Anectine is more likely to generate stable, modest portfolio contribution than material standalone growth. A supplier with excess sterile-injectable capacity can improve economics through manufacturing scale and distribution density. A supplier with a constrained facility may experience the opposite result: low list prices combined with high compliance, inventory, and remediation costs.

Shortage periods can temporarily improve realized pricing, but the benefit may be offset by expedited production, constrained capacity, customer allocation, and regulatory remediation costs. The product's most valuable financial characteristic is often its role in a broader hospital-injectable portfolio.

What is the competitive landscape for Anectine?

Direct succinylcholine competitors

Direct competitors are products labeled as succinylcholine chloride injection or equivalent presentations. The commercial set can include branded legacy products, authorized generics, and conventional generic injectables. Availability varies by country and over time.

Therapeutic competitors

Product	Competitive advantage	Competitive limitation
Succinylcholine	Very rapid onset and short duration	Hyperkalemia and malignant-hyperthermia risks
Rocuronium	Broad use in rapid-sequence intubation; reversible with sugammadex	Longer duration and higher total treatment cost in some settings
Vecuronium	Established nondepolarizing agent	Slower onset than succinylcholine in many protocols
Atracurium	Useful in selected surgical and intensive-care settings	Histamine-related effects and less rapid onset

The competitive threat is not limited to another succinylcholine manufacturer. Protocol changes that favor rocuronium can reduce the entire succinylcholine market, including Anectine.

Which companies are challenging Anectine?

The relevant challengers are manufacturers of generic succinylcholine injections and suppliers of competing neuromuscular blockers. In the United States, hospital injectable competition has historically included large generic and branded manufacturers such as Pfizer, Hikma, Sandoz, Fresenius Kabi, and other approved suppliers, depending on the specific product and period.

Competition is usually not litigation-led. It is driven by:

• abbreviated new drug application approval;
• contract tenders;
• wholesaler access;
• supply continuity;
• manufacturing capacity;
• drug-shortage allocation;
• hospital formulary preference.

The market has limited value for a Paragraph IV campaign because the principal active ingredient is long off patent. A new entrant is more likely to pursue regulatory approval and commercial contracting than patent litigation.

Are there Paragraph IV challenges involving Anectine?

No material current Paragraph IV dispute is central to the commercial outlook for Anectine. A Paragraph IV certification is relevant when a generic applicant challenges an Orange Book-listed patent. Anectine's core commercial problem is not patent vulnerability. It is mature generic competition and the economics of sterile injectable supply.

A future dispute could involve a specific device, packaging system, formulation, or manufacturing patent, but such a dispute would be product-specific and would not restore exclusivity for conventional succinylcholine chloride injection.

What formulation patents protect Anectine?

No current formulation patent is known to provide Anectine with a broad commercial moat. Conventional vials and injectable solutions are generally exposed to generic competition once regulatory requirements are satisfied.

Possible differentiation could arise from:

• preservative-free presentations;
• prefilled syringes;
• ready-to-administer products;
• improved stability;
• reduced preparation steps;
• specialized emergency packaging.

These features can support contracting or operational advantages, but they would need meaningful adoption and enforceable intellectual-property rights to materially change the market structure.

What manufacturing and IP barriers affect Anectine?

Manufacturing barriers are more significant than patent barriers. Critical factors include:

1. Sterile filling capacity.
2. Validated container-closure systems.
3. Active pharmaceutical ingredient supply.
4. Environmental monitoring and aseptic-process controls.
5. Stability data across storage conditions.
6. FDA inspection history.
7. Cold-chain and distribution requirements where applicable.
8. Ability to maintain supply during facility disruption.

An established supplier can benefit from operational reliability even when the product is legally commoditized. Conversely, a supplier with a quality event can lose hospital contracts quickly because customers often maintain approved alternatives.

What is the generic launch outlook for Anectine?

The probability of a patent-blocked generic launch is low. The more relevant launch scenarios are:

Scenario	Market effect
New generic entrant with reliable supply	Lower contract prices and share dilution
Existing supplier exits	Temporary shortage and share reallocation
Manufacturing disruption	Allocation, emergency sourcing and temporary price increases
Increased rocuronium use	Structural volume decline for succinylcholine
New ready-to-use presentation	Limited premium opportunity
Hospital purchasing consolidation	Greater price pressure on suppliers

The most credible commercial upside would come from securing supply contracts during a competitor shortage or offering a differentiated ready-to-use presentation. Neither scenario supports a durable branded pricing premium without meaningful product differentiation.

What is the geographic market for Anectine?

Anectine's commercial status varies by country. The brand name may be used in some markets while equivalent products are sold under generic names or different local brands elsewhere. Regulatory authorization, reimbursement, hospital procurement, and shortage conditions are jurisdiction-specific.

The United States is characterized by:

• FDA-approved injectable products;
• hospital and wholesaler purchasing;
• Orange Book and abbreviated-approval pathways;
• periodic sterile-injectable shortages;
• strong generic substitution.

European and other international markets can have different brand ownership, national tender systems, labeling conventions, and reimbursement rules. In many non-U.S. markets, the name "suxamethonium" is more common than "succinylcholine."

What litigation and settlement risks affect Anectine?

Patent litigation and settlement risk are low for conventional Anectine. The main legal and regulatory exposures are:

• product-liability claims involving known serious adverse reactions;
• manufacturing-related enforcement;
• labeling disputes;
• supply-contract disputes;
• antitrust scrutiny if shortages coincide with unusual price movements;
• intellectual-property disputes over delivery systems or packaging.

There is no clear basis for expecting a major litigation-driven transfer of value comparable to disputes involving protected branded medicines.

Key Takeaways

• Anectine is a legacy succinylcholine chloride injection product with no material current patent moat.
• Its market is mature, price-sensitive, and dominated by hospitals, wholesalers, group purchasing organizations, and generic suppliers.
• Standalone Anectine revenue and profitability are not publicly disclosed.
• Financial performance depends more on sterile-manufacturing reliability and contracts than on brand strength.
• Shortages can produce temporary pricing and share benefits, but they do not create durable exclusivity.
• Rocuronium is the principal therapeutic substitute and creates long-term volume pressure.
• Paragraph IV litigation and patent-settlement risk are low.
• The most important commercial barriers are aseptic manufacturing, regulatory compliance, supply continuity, and distribution access.
• The likely forward trajectory is stable-to-declining volume with continued low pricing, interrupted by temporary supply-driven opportunities.

FAQs

Is Anectine still commercially available?

Availability depends on country, supplier, presentation, and current inventory. Equivalent succinylcholine injection products may be marketed under generic or different brand names.

Is Anectine more expensive than rocuronium?

The answer depends on dose, hospital contract pricing, vial waste, and whether sugammadex is used with rocuronium. Acquisition cost alone does not determine total treatment cost.

Can a generic manufacturer launch succinylcholine without challenging Anectine patents?

Yes. Because the core molecule is long off patent, a conventional generic applicant generally does not need to overcome a meaningful composition-of-matter patent barrier.

Does Anectine have biosimilar competition?

No. Anectine is a small-molecule chemical drug, not a biologic. Its competitors are generic injectable products and alternative neuromuscular blockers, not biosimilars.

What would increase the value of an Anectine product?

Reliable supply, FDA-compliant sterile manufacturing, favorable hospital contracts, reduced preparation burden, and a differentiated ready-to-use presentation would provide the strongest commercial advantages.

References

1. U.S. Food and Drug Administration. (2023). Anectine (succinylcholine chloride injection, USP) prescribing information. FDA.
2. U.S. Food and Drug Administration. (n.d.). Drug shortages database. FDA.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. FDA.
5. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.